20/20 Biolabs, Inc. (AIDX)
20/20 Biolabs will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
20/20 Biolabs Revenue
20/20 Biolabs had revenue of $2.04M in the twelve months ending September 30, 2025. In the year 2024, 20/20 Biolabs had annual revenue of $1.75M with 23.03% growth.
Revenue (ttm)
$2.04M
Revenue Growth
+23.03%
P/S Ratio
n/a
Revenue / Employee
$85,123
Employees
24
Market Cap
n/a
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.75M | 328.04K | 23.03% |
| Dec 31, 2023 | 1.42M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAIDX News
- 17 hours ago - 20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress - GlobeNewsWire
- 7 days ago - 20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026 - GlobeNewsWire
- 8 days ago - 20/20 BioLabs enters licensing agreement with University of South Carolina - TheFly
- 9 days ago - 20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina - GlobeNewsWire
- 9 days ago - 20/20 BioLabs initiated with a Buy at Maxim - TheFly
- 6 weeks ago - 20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform - GlobeNewsWire
- 6 weeks ago - 20/20 BioLabs files to sell 10.1M shares of common stock for holders - TheFly
- 7 weeks ago - 20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress - GlobeNewsWire